SCHEDULE: WuXi Entities Adjust Adagene Stake Disclosure
Beneficial Ownership Filing (Schedule 13G Amendment)
WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. have updated their Schedule 13G filing regarding their beneficial ownership of Adagene Inc. ordinary shares.
Summary
- WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. have filed an amendment to their Schedule 13G filing concerning Adagene Inc.
- The filing indicates that WuXi PharmaTech Healthcare Fund I L.P. directly holds 2,891,594 ordinary shares, represented by 2,313,275 American Depositary Shares (ADS).
- WuXi AppTec Co., Ltd. is identified as the indirect parent company and ultimate beneficial owner of these shares, holding voting and investment authority.
- The total beneficial ownership reported is 2,891,594 ordinary shares, representing 3.5% of the class.
- This filing is an amendment (Amendment No. 4) and the event date requiring the filing is June 30, 2026.
- The reporting persons expressly disclaim status as a 'group' for the purposes of this Schedule 13G.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily reflecting a change in reporting status rather than significant new information about the company's performance or strategy.
Positives
- The filing clarifies the ownership structure and beneficial interest of WuXi entities in Adagene Inc.
- The reporting persons have updated their disclosure, ensuring compliance with regulatory requirements.
Negatives
- The filing does not provide new financial performance data or strategic updates for Adagene Inc.
Risks
- The filing does not explicitly mention any new risks or changes to existing risk factors for Adagene Inc.
Future Outlook
The filing does not contain forward-looking statements or guidance from Adagene Inc. management.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial ownership changes or updates. This filing by WuXi entities appears to be an administrative update rather than a reflection of new strategic direction or performance for Adagene Inc.
Stakeholder Impact
- Shareholders: The filing provides transparency on significant ownership stakes, which is standard for regulatory compliance and investor information.
Key Dates
| Date | Description |
|---|---|
| 01/07/2021 | Date of Joint Filing Agreement by WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. |
| 01/08/2021 | Date of initial Schedule 13G filing referenced in the Joint Filing Agreement. |
| 04/02/2026 | Date of Adagene Inc.'s prospectus supplement filed with the SEC. |
| 04/06/2026 | Date as of which Adagene Inc.'s ordinary shares outstanding were reported in the prospectus supplement. |
| 06/30/2026 | Date of Event Which Requires Filing of this Statement (Amendment No. 4). |
| 08/14/2026 | Date of signatures for the Schedule 13G filing. |
Keywords
Adagene Inc., Schedule 13G, WuXi PharmaTech Healthcare Fund I L.P., WuXi AppTec Co., Ltd., Beneficial Ownership, Ordinary Shares, American Depositary Shares, Ownership Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.